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Abstract
Machado-Joseph disease (MJD) is an inherited neurodegenerative disease, caused by a
CAG repeat expansion within the coding region of ATXN3 gene, and which currently lacks
effective treatment. In this work we tested the therapeutic efficacy of chronic treatment with
valproic acid (VPA) (200mg/kg), a compound with known neuroprotection activity, and pre-
viously shown to be effective in cell, fly and nematode models of MJD. We show that chronic
VPA treatment in the CMVMJD135 mouse model had limited effects in the motor deficits of
these mice, seen mostly at late stages in the motor swimming, beam walk, rotarod and
spontaneous locomotor activity tests, and did not modify the ATXN3 inclusion load and
astrogliosis in affected brain regions. However, VPA chronic treatment was able to increase
GRP78 protein levels at 30 weeks of age, one of its known neuroprotective effects, confirm-
ing target engagement. In spite of limited results, the use of another dosage of VPA or of
VPA in a combined therapy with molecules targeting other pathways, cannot be excluded
as potential strategies for MJD therapeutics.
Introduction
Polyglutamine (PolyQ) diseases are neurodegenerative disorders caused by an expansion of tri-
nucleotide CAG repeats within the coding region of specific genes [1]. This group of disorders
includes spinal bulbar muscular atrophy (SBMA), Huntington’s disease (HD), Dentatorubral-
Pallidoluysian atrophy (DRPLA), and six types of spinocerebellar ataxias (SCA’s) [2].
Machado-Joseph disease (MJD) or Spinocerebellar Ataxia type 3 (SCA3) is the most common
dominantly inherited SCA worldwide and is caused by the expansion of a polyQ tract in the C-
terminus of the ATXN3 gene product [3]. Both the normal and expanded ataxin-3 (ATXN3)
proteins are expressed ubiquitously, although the neurodegeneration in MJD is limited to some
brain regions, mainly in cerebellum, brainstem and spinal cord [4]. The symptoms include
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ataxia, progressive external ophthalmoplegia, pyramidal and extrapyramidal signs, peripheral
amyotrophies, intention fasciculation-like movements of facial and lingual muscles, rigidity,
and bulging eyes [5–7]. The pathological hallmark of the disease is the presence of neuronal
intranuclear inclusions (NIIs) of aggregation-prone expanded ATXN3 in the patients' brain,
being the pathogenic relevance of these aggregates still unclear [8–11].
Despite the recent efforts towards the understanding of the pathogenesis of this disorder,
the molecular pathways that ultimately lead to neuronal demise remain mostly unknown and
no effective treatments are yet available for MJD, as for other polyQ diseases. Nevertheless,
there seem to be common pathways between all polyQ diseases that were shown to be altered,
which could be explored in the development of therapeutics, related to transcriptional dysregu-
lation, mitochondrial dysfunction, oxidative stress, Ubiquitine Proteasome System (UPS)
impairment, excitotoxicity, DNA damage and activation of apoptotic pathways [12].
Nevertheless, the translation of candidate therapies to clinical trials is a very long process
due to uncertainty for human safety and has not improved significantly in the last years. In this
context, drug re-purposing strategies, which relies on finding new uses for existing FDA-
approved compounds, has been gaining attractiveness due to the faster translation to the clinic,
with predictably less safety issues.
VPA is an FDA-approved compound that has been used over the years as an anticonvulsant
and mood-stabilizing drug in the treatment of epilepsy, bipolar disorder and migraine [13], with
a relatively safe profile in clinical use. In the last years, a growing body of evidence indicates that
VPA holds promise in treating other neurodegenerative diseases due to its diverse mechanisms
of action. Its pharmacological effects comprise a range of mechanisms, including inhibition of
histone deacetylases, increased gamma-aminobutyric acid (GABA)-ergic transmission, reduced
release and/or effects of excitatory amino acids, blockade of voltage-gated sodium channels and
modulation of dopaminergic and serotoninergic transmission [14]. VPA treatment is also known
to produce changes in the expression of multiple genes, involved in transcription regulation, cell
survival, ion homeostasis, cytoskeletal modifications, signal transduction, endoplasmic reticulum
stress and longevity [13,15] This drug has been shown to delay the disease onset, to reduce neuro-
logical deficits and/or to prolong survival in several models of neurodegenerative diseases, includ-
ing HD, SBMA and Amyotrophic Lateral Sclerosis (ALS) [16–18]. In MJD, VPA was reported to
alleviate neurodegeneration in a Drosophilamodel of the disease [19] and to attenuate mutant
ATXN3-induced cell toxicity in a human neuronal cell model [20]. Moreover, we have previously
shown a significant reduction of mutant ATXN3 aggregation and neurological dysfunction in a
C. elegansmodel of MJD upon VPA treatment through the protective role of the transcription
factor DAF-16, supporting a role in protection against proteotoxicity related to aging and cell
survival [21]. However, its therapeutic efficacy is still not demonstrated in a mammalian model
of MJD. The goal of this work was to test the therapeutic efficacy of chronic VPA treatment in a
mouse model of MJD, CMVMJD135 [22]. Our results show that chronic VPA treatment at the
dosage used in this pre-clinical trial, lead to very limited and transient phenotypic effects in the
CMVMJD135 mouse model, and did not change the ATXN3 inclusion load neither astrogliosis
in affected brain regions.
Results
Effect of VPA acute treatment in histone acetylation and neuroprotective
molecules in the cerebellum
Although CMVMJD135 mouse model do not present a general hypoacetylation of histones in
specific brain regions, we measured the H3 acetylation and we observed a trend towards an
increase in H3 acetylation levels upon 5 days of VPA acute treatment (Fig 1A)
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This result did not present statistical difference due to high variability between samples,
however, a trend was observed to an hyperacetylation of histone H3 in the cerebellum upon
VPA treatment, when normalized to the nuclear protein Lamin B1. Furthermore, and consid-
ering our previous results in C.elegansmodel of MJD upon VPA treatment, we also assessed
the mRNA levels of GADD45α and BIM, two genes related to stress resistance and apoptosis
regulation, respectively [23–26], in the cerebellum of CMVMJD135 mice, where a trend
towards an increase upon VPA acute treatment was also observed (Fig 1B).
Fig 1. VPA acute treatment effects in cerebellum of CMVMJD135mousemodel. (A) A trend towards an increase in the H3 histone acetylation upon VPA
acute treatment; (B) a trend towards an increase in GADD45α and BIM mRNA levels upon VPA acute treatment and (C) VPA concentration in the plasma
after 30 and 120 minutes post-injection. Bars represent the mean ± SEM (n = 4 males for each group), One-Way ANOVA.
doi:10.1371/journal.pone.0141610.g001
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Plasma VPA concentration was also assessed after 30 and 120 minutes post-injection. An
average of 252 ± 15.8 μmol/L after 30 minutes was observed in VPA-treated animals while a
25.7 ± 8.7 μmol/L concentration was detected after 120 minutes post-injection (Fig 1C).
VPA treatment had limited effects in neurological deficits and decreased
the body weight gain in CMVMJD135 mice
Chronic VPA treatment was initiated at 5 weeks of age, with a dosage of 200mg/kg, for 5 conse-
cutive days each week, until 30 weeks of age. A battery of neurological and motor coordination
tests was performed since 4 weeks of age until 30 weeks of age (Fig 2).
No differences were found betweenWT and CMVMJD135 mice at 4 weeks of age before the
beginning of the injections. CMVMJD135 mice start showing less body weight gain at 16 weeks
of age, being statistically different from age-matchedWT littermates at 24 weeks of age (Fig 3A).
VPA treatment significantly reduced the already diminished body weight gain of the transgenic
animals since very early in this trial (Fig 3A) suggesting some toxicity to these animals.
Other than reduced weight gain, no apparent clinical symptoms indicative of significant
health impact were observed during long-term VPA treatment of WT and transgenic animals,
and no more than 20% of their total body weight was lost at any instance. The first sign of neu-
rological disease in the CMVMJD135 mouse model is the presence of muscular grip strength
abnormalities at 6 weeks of age, given by the significant decrease in the latency to fall off in the
hanging wire test [22]. VPA treatment did not alter the progression of the CMVMJD135 ani-
mals in the hanging wire, demonstrating an absence of effect in muscle strength and/or fine
motor coordination of the paws (Fig 3B). Spontaneous locomotor activity of transgenic ani-
mals, given by the number of squares travelled in the arena, was markedly increased upon VPA
treatment at 24 weeks of age (Fig 3C). However, spontaneous vertical exploratory activity,
tremors and clasping were not improved by VPA treatment (Fig 3D, 3E and 3F).
Fig 2. Schematic representation of the VPA pre-clinical therapeutic trial.
doi:10.1371/journal.pone.0141610.g002
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Fig 3. Minor effects in neurological deficits and body weight gain presented by CMVMJD135mice upon VPA treatment. (A) Decreased body weight
gain in CMVMJD135 VPA-treated animals compared to CMVMJD135 vehicle-treated animals; (B) no improvement of VPA-treated animals in grip strength as
assessed through the hanging wire test; (C) Improvement in spontaneous locomotor activity at 24 weeks of age; (D,E,F) No improvement in spontaneous
activity (vertical movement), in tremors and limb clasping, respectively, (G) transient improvement in footdragging severity at 14 weeks, and (H) tendency
toward an improvement in stride length at 22 and 24 weeks of age. Bars represent the mean ± SEM (WT veh, n = 10; WT VPA, n = 15; CMVMJD135 vehicle,
n = 10; CMVMJD135 VPA, n = 13), * represent p<0.05, ** represent p<0.01 and *** represent p<0.001, black asterisks represents the difference between
WT and CMVMJD135, blue asterisks represents the difference between non-treated and VPA-treated CMVMJD135 (Repeated-measures ANOVA, Tukey
correction for continuous variables, One-Way ANOVA for differences between groups in specific ages of the continuous variables and Chi-square Fisher’s
exact test for categorical non-continuous variables).
doi:10.1371/journal.pone.0141610.g003
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Gait abnormalities were assessed qualitatively by the analysis of the footprint pattern.
CMVMJD135 mice model presented foot dragging already at 12 weeks progressing through
age. VPA was able to decrease the severity of this phenotype only at 14 weeks (Fig 3G), while
no effect was observed at more advanced stages of the trial. In addition, stride length was also
measured and although not significant, a trend towards and improvement in transgenic ani-
mals upon VPA treatment was observed at 22 and 24 weeks of age (Fig 3H).
Long-term VPA treatment led to limited improvement in balance and
motor coordination at later disease stages
Since chronic VPA treatment induced a decrease in body weight of transgenic animals, behav-
ior performance in the motor and balance coordination tests was normalized to body weight.
Results of behavioral tests without normalization to body weight are included in supplemen-
tary data (S1 Fig).
VPA treatment ameliorated balance and motor coordination of CMVMJD135 mice at 24
weeks of age, after 20 weeks of daily treatment, as assessed by the time taken to cross the 11
mm circle and 12 mm beams in the balance beam walk test. However, this improvement was
not maintained at 30 weeks of age (Fig 4A and 4B).
Fig 4. Balance andmotor coordination performance normalized for animal body weight. (A,B) No differences were observed between non-normalized
and normalized performance for body weight in balance beam walk test; (C) improvement motor swimming test at 22 and 30 weeks of age and (D)
improvement at 22 weeks of in 8 and 20 rpm of Rotarod test. Bars represent the mean ± SEM (WT veh, n = 10; WT VPA, n = 15, CMVMJD135 vehicle, n = 10;
CMVMJD135 VPA, n = 13), * represent p<0.05, ** represent p<0.01 and *** represent p<0.001, black asterisks represents the difference betweenWT and
CMVMJD135, blue asterisks represents the difference between non-treated and VPA-treated CMVMJD135, (Repeated-measures ANOVA, Tukey correction
for continuous variables, One-Way ANOVA for differences between groups in specific ages of the continuous variables and Mann-Whitney U test for
continuous variables without normal distribution (Rotarod).
doi:10.1371/journal.pone.0141610.g004
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In the motor swimming test, VPA-treated CMVMJD135 mice also had a better performance
later in life (22 and 30 weeks of age) when compared to vehicle-treated mice (Fig 4C). Other
motor deficits observed in CMVMJD135 mice, namely the loss of motor coordination observed
in the Rotarod test, were alleviated by VPA treatment at 22 weeks of age for 8 and 20 rpm, but
not maintained at 30 weeks of age. (Fig 4D and 4E).
VPA treatment did not change the ataxin-3 inclusion load and
astrogliosis in specific brain regions of CMVMJD135 mice
At the pathological level, CMVMJD135 mice show presence of ATXN3 NIIs in the nucleus of
cells in different regions of the CNS including the pontine nuclei, reticulotegmental nucleus of
the pons, spinal cord neurons, facial motor nuclei, anterior olfactory nuclei, ventral tenia tecta,
inferior olive, dentate nuclei, locus coeruleus, cuneate nuclei and lateral reticular nuclei [22].
The analysis of brain tissue of VPA-treated and non-treated CMVMJD135 by immunohis-
tochemistry of ATXN3 in facial motor nuclei (7N) and lateral reticular nuclei (LRt), did not
reveal significant differences between groups (Fig 5A–5D).
Astrogliosis observed in substantia nigra of the CMVMJD135 mouse model, was also not
mitigated upon VPA treatment (Fig 5E and 5F).
Chronic VPA treatment increases GRP78 protein levels in cerebellum of
CMVMJD135 mice
One of the neuroprotective actions described for VPA is its ability to increase GRP78 protein
levels, through HDAC inhibition [15]. GRP78, also known as binding immunoglobulin protein
(BiP), is a stress chaperone protein found in the lumen of the endoplasmic reticulum (ER)
which binds newly synthesized proteins as they are translocated into the ER, and keeps them in
a competent state for subsequent folding and oligomerization [27]. We specifically investigated
the potential role of HDAC inhibition by monitoring the GRP78 protein levels induction upon
VPA treatment. We observe a striking increase in GRP78 protein levels in
CMVMJD135-treated animals when compared to non-treated animals, in the cerebellum at 30
weeks of age (Fig 6).
Discussion
In the past years, the use of VPA as a treatment for neurodegenerative disease models has been
shown to improve neurological phenotypes, decrease cell degeneration and toxicity, together
with the increase of histone acetylation and subsequent gene transcription activation [28–33].
The dosage of VPA of 200mg/kg used in this pre-clinical trial was previously described in a
pre-clinical trial ALS, in which neuroprotective and histone acetylation effects were shown
[34,35]. Here, we also show that five days treatment with 200mg/kg of VPA was able to exert a
trend towards an increase in histone acetylation in cerebellum and a tendency to increase
GADD45α and BIM mRNA levels, which may be used as VPA target engagement [36–38].
The acute treatment and/or high variability between animals may account for the lack of statis-
tical differences between groups. Acute VPA treated animals presented therapeutic levels of
252 ± 15.8 μmol/L and 25.7 ± 8.7 μmol/L in plasma, after 30 and 120 minutes post-injection,
respectively, which was within the usually accepted therapeutic range of VPA. Therefore, we
performed a pre-clinical trial with five consecutive day treatment starting at 5 and ending at 30
weeks of age in CMVMJD135 mouse model. Animals in the pre-clinical trial were always
maintained in an appropriate and healthy environment avoiding the development of any
stressful condition that may interfere with their motor performance. Although previous
Chronic VPA Treatment in CMVMJD135 Mouse Model
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findings by several groups suggested a therapeutic effect for VPA in cellular and invertebrate
animal models of SCA3, in the present study, chronic VPA treatment of CMVMJD135 mice
lead to a late and limited improvement in the motor performance, given by the beam balance,
motor swimming, rotarod and spontaneous locomotor activity tests. For other general health
and neuromuscular function, VPA-treatment had only marginal or even no effects comparing
Fig 5. Immnuhistochemistry and quantification of ATXN3 neuronal inclusions and astrogliosis of VPA-treated and non-treated CMVMJD135.No
differences in nuclear ATXN3 inclusion load were observed between groups in (A,B) 7N and (C,D) LRt brain regions. No differences in astrogliosis in
substantia nigra (SN) between VPA-treated and non-treated transgenic animals (E,F). Scale bar of ATXN3 figures, 20 μm; Scale bar of GFAP figure, 200 μm.
Bars represent the mean ± SEM (n = 4 for each group), One-Way ANOVA.
doi:10.1371/journal.pone.0141610.g005
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to vehicle-treated transgenic animals. In addition, the dosage used in this study is not consid-
ered toxic for mice and is already described as safe in the literature [18,34,35,39]. Nevertheless,
chronic VPA treatment at similar dosage was already described to reduce the body mass gain
in WT animals [34], even though chronically treated human patients are known to increase
their body weight upon VPA treatment [40–42]. Metabolic differences and biological system
diversity could be the reason for these contradictory observations.
At the pathological level, we examined the presence of ATXN3 neuronal nuclear inclusions
in facial nuclei (7N) and lateral reticular nuclei (LRt), two regions described to be affected in
MJD human patients [43,44], as well as in CMVMJD135 mouse model [22]. No differences
were observed in the amount of nuclear neuronal inclusions of ATXN3 in both VPA-treated
and non-treated CMVMJD135 mice.
Additionally, astrogliosis is a consistent pathological phenotype of CMVMJD135 mouse
model and human patients, which was also not mitigated by VPA chronic treatment.
The overexpression of specific chaperones has been shown to allow protection against cellu-
lar damage and/or death caused from an extensive group of agents and conditions including
cytotoxic chemicals [45], oxidative stress [46] and ER stress [27]. Here we show that the induc-
tion of GRP78 protein levels upon VPA chronic treatment, whose overexpression may be neu-
roprotective in proteinopathies, including MJD [47,48], could be one of its cytoprotective
actions in the MJD context, enhancing the folding capacity of the ER. The induction of GRP78
Fig 6. Cerebellum western-blot and quantification of GRP78 protein levels in 30 week-old WT, VPA-
treated and non-treated CMVMJD135mice.GRP78 protein induction in CMVMJD135 animals upon VPA
treatment. Bars represent the mean ± SEM (n = 4 for each group), * represent p<0.05, One-way ANOVA.
doi:10.1371/journal.pone.0141610.g006
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also indicates VPA target engagement during the chronic treatment in the pre-clinical trial, as
this protein is known to be induced by VPA [15]. Although we did not observe a statistical dif-
ference in the CMVMJD135 animals when comparing to WT, enhancing the expression of this
molecular chaperone in the cerebellum of these mice could be one of the neuroprotective
mechanisms responsible for the late and mild improvement of the CMVMJD135 animal motor
performance.
The observed beneficial effects of VPA were transient, occurred mostly later in life and thus
at an advanced stage of disease (between 22 and 30 weeks of age), mainly in behavioral tests
more related with motor coordination. These results are comparable to some extent with previ-
ous findings, in which we have shown a significant reduction in neurological dysfunction in a
C. elegansmodel of MJD after VPA treatment that was more relevant later in the worm’s life
(day10) in spite of early treatment [21]. Previous evidence also suggested a protective role for
VPA in the context of MJD, both in cell and Drosophilamodels, by attenuating mutant
ATXN3 induced cell toxicity and alleviating polyQ-induced phenotypic abnormalities, without
major impact on ATXN3 inclusion [19,20]; in C. elegans, there was some improvement of
aggregation, but less prominent than that observed for other compounds, for instance Hsp90
inhibitors [21].
Although the effects observed in our mouse model were not striking, only one dosage of
VPA was tested; thus, the possibility of testing other dosages, far from toxic and lethal ones
[49,50], should be considered, as they could exert more pronounced effects. Moreover, the
complex activity and a broad range of VPA effects also create the need for further clarification
of the effects of this drug not only at the symptom level, but also molecular and pathological
levels in the CMVMJD135 mouse model. In fact, and although the use of HDACi’s in the con-
text of polyQ diseases has showed promising results, the evidence for a globally decreased his-
tone acetylation is not fully consistent [51], and this strategy still lacks some target specificity/
selectivity [52] and requires a more in depth study of the mechanisms of action of these com-
pounds in the central nervous system. Furthermore, chronic VPA treatment in human patients
can produce some side effects, such as weight gain [53,54], decreased reproductive potential
[55,56] and increased susceptibility to birth defects [57–59]. Nevertheless, the strategy of re-
purposing FDA/EMA-approved molecules, as VPA, could be of benefit for MJD and other rare
diseases lacking effective therapies. Additionally, there is still an open window for different
VPA dosages to be tested and since in the past years, a growing number of efforts are being
developed for the formulation of a new generation of more selective and specific compounds
this could be useful for the treatment not only of MJD, but also of other polyglutamine
diseases.
Material and Methods
Ethics statement
All animal procedures were conducted in accordance with European regulations (European
Union Directive 86/609/EEC). Animal facilities and the people directly involved in animal
experiments (SE, SDS, ANC and ASF) were certified by the Portuguese regulatory entity—
Direcção Geral de Alimentação e Veterinária. All of the protocols performed were approved by
the Ethics Subcommittee for Life and Health Sciences of the Life and Health Sciences Research
Institute, University of Minho. All experiments were designed with commitment to the princi-
ples of refinement, reduction, and replacement and performed according to the FELASA
guidelines to minimize discomfort, stress, and pain to the animals, with defined humane end-
points [60]. Humane endpoints for the preclinical trial were defined as 20% reduction of the
body weight, inability to reach food and water, presence of wounds in the body and
Chronic VPA Treatment in CMVMJD135 Mouse Model
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dehydration), however they were not needed as the study period was conceived to include ages
at which animals do not reach these endpoints.
Transgenic mice model and drug administration
We used the CMVMJD135 (background C57BL/6) mouse model, expressing an expanded ver-
sion of the human MJD1-1 cDNA (the 3 UIMs-containing variant of ATXN3) under the regu-
lation of the CMV promoter, ubiquitously and at near-endogenous levels [22]. These animals
show a slowly progressive motor phenotype and CNS pathology consistent with that of MJD
patients [22]. Male transgenic and non-transgenic drug- and placebo- treated animals were
sequentially assigned and housed at weaning in groups of 5 animals in filter-topped polysul-
fone cages 267 × 207 × 140 mm (370 cm2 floor area) (Tecniplast, Buguggiate, Italy), with corn-
cob bedding (Scobis Due, Mucedola SRL, Settimo Milanese, Italy) in a conventional animal
facility. DNA extraction, animal genotyping and CAG repeat size analyses were performed as
previously described [61], with the mean repeat size (±SD) for all mice of (133±1). Male litter-
mates wild-type (WT) animals were used as controls. All animals were maintained under stan-
dard laboratory conditions: an artificial 12 h light/dark cycle (lights on from 8:00 to 20:00 h),
with an ambient temperature of 21±1°C and a relative humidity of 50–60%; the mice were
given a standard diet (4RF25 during the gestation and postnatal periods, and 4RF21 after wean-
ing, Mucedola SRL, Settimo Milanese, Italy) and water ad libitum. We administered Valproic
acid sodium salt (PG-4543, Sigma) during five consecutive days per week through intraperito-
neal injection (i.p), in a dosage of 200mg/kg dissolved in 0,9% saline. Control animals were
given a placebo of injection buffer (0.9% NaCl) with the same frequency. Treatment was initi-
ated at five weeks of age, i.e. one week before the onset of the first neurological symptoms, until
30 weeks of age of the pre-clinical trial. For a pilot study, WT animals were treated for 5 conse-
cutive days with i.p. injections of VPA at 200mg/kg or saline.
Western-blot analysis
Cerebellum tissues were thawed and homogenized with a Potter-Elvejhem 377 homogenizer
with a Teflon pestle, at 300 rpm, in lysis buffer (150 mMNaCl, 50 mM Tris, 5 mM EGTA, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.5) supplemented with 100 nM oka-
daic acid, 25 mMNaF, 1 mMNa3VO4, 1 mMDTT, 1 mM PMSF, 1 μg/mL of protease inhibi-
tor cocktail (chymostatin, pepstatin A, leupeptin and antipain), 1 μM trichostatin A (HDACs
inhibitor) and 10 mM nicotinamide (sirtuins inhibitor). The homogenates were then sonicated
for 15 s and centrifuged at 20,800 g for 10 min to remove cell debris. The pellet was discarded,
the supernatant (total extract) was collected and protein content quantified by Bio-Rad protein
assay (Bio-Rad). Total extracts were denatured with denaturing buffer (50 mM Tris-HCl pH
6.8, 2% SDS, 5% glycerol, 600 mM DTT, 0.01% bromophenol blue) at 95°C, for 5 min. Equiva-
lent amounts of protein (30μg) were separated on a 15% SDS-PAGE gel electrophoresis and
electroblotted onto polyvinylidene difuoride (PVDF) membranes. The membranes were
blocked for 1 h in Tris-buffered saline (TBS) solution containing 0.1% Tween (TBS-Tween)
and 5% BSA, followed by an overnight incubation with primary antibodies (rabbit anti-acH3
(1:1000, Milipore), rabbit anti-Lamin B1 (1:1000, Abcam) rabbit anti-GRP78 (1:1000, Abcam)
and mouse anti-actin (1:5000, Ambion), at 4°C, with gentle agitation. Membranes were then
washed 3 times, for 10 min, with TBS-Tween, and incubated with secondary antibodies conju-
gated with alkaline phosphatase (1:10000), for 1 h, at room temperature, with gentle agitation.
Immunoreactive bands were visualized by alkaline phosphatase activity after incubation with
ECL substrate, in a ChemiDoc Imaging System (Bio-Rad). Bands were quantified using the
Image Lab software (Bio-Rad).
Chronic VPA Treatment in CMVMJD135 Mouse Model
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Gene expression quantification (qRT-PCR)
Cerebellum total RNA was isolated from 18 week-old CMVMJD135 littermate mice, vehicle-
and VPA-treated (n = 4 for each group) using TRIZOL (15596–026, Invitrogen, Calrsbad,
USA) according to the manufacturer’s protocol. RNA samples were treated with DNase I
(EN0525, Thermo Scientific1, USA) according to the manufacturer’s protocol. First-strand
cDNA, synthesized with iScript cDNA Synthesis kit (#170–8891, Bio-Rad, USA) was amplified
by quantitative reverse-transcriptase PCR (qRT-PCR) as previously described [22]. The following
primers were used for expression quantification: GADD45α (F 5-AGACCGAAAGGATGGAC
ACG-3’); GADD45α (R 5’-TGACTCCGAGCCTTGCTGA-3’); BIM (F 5’-CGGATCGGAGAC
GAGTTCA-3’); BIM (R 5’-TTCAGCCTCGCGGTAATCA-3’); B2m (F 5’-CCTTCAGCAAGGA
CTGGTCT-3’ and B2m (R 5’-TCTCGATCCCAGTAGACGGT-3’). Primers were designed
using PRIMER-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).
Behavioral analysis
Behavioral analysis was performed during the diurnal period in groups of 5 male animals per
cage including CMVMJD135 hemizygous transgenic mice and WT littermates (n = 10–15 per
genotype) treated and non-treated with VPA. All behavioral tests started in a pre-symptomatic
stage of the disease (4 weeks of age) and were conducted until an age at which the phenotype is
fully established (30 weeks) [22]. The animals were weighed one week before the start of drug
treatment (4 weeks) and then every two weeks until 30 weeks of age (Fig 2).
Neurological examination (based on SHIRPA protocol). Based on the SHIRPA protocol
we established an adapted protocol for phenotypic assessment applied since 4 weeks until 24
weeks of age, in which we used the tests for which, based on our previous experience,
CMVMJD135 mice usually present significant phenotypic alterations [22]. We assessed motor
function through the spontaneous activity test, by counting wall-leanings during five minutes,
and locomotor activity in which we counted the number of squares travelled over 30 secs, in an
arena (55×33×18 cm) with 15 labeled squares. Other observational measurements included
tremors and limb clasping, in which we suspended the animal by the tail and classified the
extensor reflexes. In this protocol we also included the hanging wire test, as a measure of mus-
cle strength and fine motor coordination of the paws. This protocol was adjusted in order to
minimize animal handling and to generate uniformity in waiting times between the tests [62].
Footprint analysis. To evaluate the dragging of the paws, the footprint test was used since
10 weeks of age. To obtain footprints, the hind‐ and forepaws of the mice were coated with
black and red non‐toxic paints, respectively. We used a clean rectangular paper sheet placed on
the floor of the runway for each run. The animals were allowed to walk along a 100‐cm‐
long × 4.2 cm width × 10 cm height corridor in the direction of an enclosed black box. Each
animal was allowed to achieve one valid trial per age. To evaluate the severity of foot-dragging
through age the footprinting pattern was classified at each time point considering six consecu-
tive steps (0 = absent dragging, up to three steps; 1 = moderate dragging, less than three steps
out of six; 2 = severe dragging, all steps out of six show dragging). The stride length was also
measured through the footprinting pattern by measuring the length between three consecutive
steps.
Motor swimming test. To assess swimming movement coordination, the time that ani-
mals take to reach a safe platform at the end of a container (60 cm distance) with 15 cm depth
of water at 24‐26°C was recorded bi-weekly since 22 weeks of age. The protocol consisted of 2
days of training with three trial followed by three days of test with two trials as previously
described [22,63].
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Beam walk test. Balance and fine motor coordination of mice were assessed by measuring
the ability of the mice to traverse, without falling, a graded series of narrow beams to reach an
enclosed safety platform as previously described [22,63]. During training, mice were placed at
the start of the 12 mm square beam and trained over 3 days (3 trials per day) to traverse the
beam to the safe platform. On the fourth day, they were tested in the training beam (12 mm
square) and 11 mm round beam (2 trials per beam).
Rotarod test. To evaluate motor skill learning and coordination with another paradigm,
mice were tested in a rotarod apparatus (TSE systems, Bad Homburg, Germany). The protocol
is comprised of 3 training days at a constant speed (15 rpm) for a maximum of 60 s in four tri-
als, with a 10 min interval between each trial. On the fourth day, animals were tested for each
of 6 different speeds (5 rpm, 8 rpm, 15 rpm, 20 rpm, 24 rpm and 31 rpm) for a maximum of
60s in two trials, with a 10-min-long interval between each trial, as previously described [61].
Immunohistochemistry and quantification of ataxin-3 neuronal inclusions
and astrogliosis
Thirty week-old WT and CMVMJD135 littermate mice, VPA-treated and non-treated (n = 4
for each group) were deeply anesthetized- with a mixture of ketamine hydrochloride (150 mg/
kg) plus medetomidine (0.3 mg/kg) and transcardially perfused with phosphate-buffered saline
(PBS) followed by 4% paraformaldehyde (PFA) (Panreac, USA). Brains were removed and
post fixed overnight in PFA 4% and embedded in paraffin. Slides with 4-μm-thick paraffin sec-
tions were subjected to antigen retrieval (Buffer Citrate, 1M) and then incubated with mouse
anti-ATXN3 (1H9) (1:1000, MAB5360, Milipore) and GFAP (1:500, Z0334, Dako corporation)
which were detected by incubation with a biotinylated anti-polyvalent antibody, followed by
detection through biotin-streptavidin coupled to horseradish peroxidase and reaction with the
DAB (3, 3'-diaminobenzidine) substrate (Lab VisionTM Ultra-VisionTM Detection kit,
Thermo Scientific). The slides were counterstained with 25% hematoxylin according to stan-
dard procedures. ATXN3 positive inclusions in the facial motor nucleus (7N) and lateral retic-
ular nucleus (LRt), and GFAP positive cells in substantia nigra (SN) of vehicle or VPA-treated
animals (n = 4 for each conditions, 4 slides per animal) were quantified and normalized for
total area using the Olympus BX51 stereological microscope (Olympus, Japan) and the Visio-
pharma integrator system software (Visopharm, Denmark) as previously described [22]. The
total area of 7N,LRT and SN were chosen based on the mouse brain atlas [64].
Determination of Valproic acid Plasma Levels
The plasma valproic acid levels were measured applying the VALP assay using the Dimension
Vista1 System (VALP Flex1 reagent cartridge)–SIEMENS.
Statistical analysis
The experimental unit used in this study was a single animal. Experimental design was based
on power analyses for optimization of sample size [65]. Mouse sample size calculations were
performed for each behavioral test and pathological analyses assuming a power of 0.8 and a sig-
nificance level of p< 0.05. The effect size was calculated aiming at detecting 50% improvement.
We used n = 10 to 15 per genotype/treatment for behavioral tests, and a group size of four ani-
mals per group for quantification of ATXN3 NIIs analysis. Data was analyzed through the
non-parametric Mann-Whitney U-test when variables were non-continuous or when a contin-
uous variable did not present a normal distribution (Kolmogorov-Smirnov test, p<0.05)
(Rotarod). Continuous variables with normal distributions and with homogeneity of variance
(Levene’s test) were analyzed with Repeated-Measures ANOVA for longitudinal multiple
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comparisons, using Tukey test for post-hoc comparisons and One-way ANOVA for paired
comparisons Non-continuous categorical variables were analyzed through Chi-Square Fisher
exact test. All statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL) and
G-Power 3.1.9.2 (University Kiel, Germany). A critical value for significance of P< 0.05 was
used throughout the study. Values were expressed as mean ± SEM for continuous variables
and as percentages for non‐continuous variables.
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given by the balance beam and motor swimming performance. (A) Amelioration of balance
and motor coordination at 24 weeks of age in 11 mm circle and (B) 12 mm square beams in
beam walk test; (C) Motor swimming coordination improvement; (D,E) no improvement in
increasing rotations in Rotarod were observed between VPA-treated and non-treated
CMVMJD135. Bars represent the mean ± SEM (WT veh, n = 10; WT VPA, n = 15,
CMVMJD135 vehicle, n = 10, CMVMJD135 VPA, n = 13),  represent p<0.05,  represent
p<0.01 and  represent p<0.001, black asterisks represents the difference between WT and
CMVMJD135, blue asterisks represents the difference between non-treated and VPA-treated
CMVMJD135, (Repeated-measures ANOVA, Tukey correction for continuous variables, One-
Way ANOVA for differences between groups in specific ages of the continuous variables and
Mann-Whitney U test for continuous variables without normal distribution (Rotarod)).
(TIF)
Acknowledgments
We are grateful to Professor Pedro Oliveira for statistical analysis support and Mrs Celina Bar-
ros, animal caretaker, for the technical support. We thank Dr. Alexandra Estrada and Dra.
Mónica Macedo from the Clinical and Pathological laboratory of Braga Hospital for the coop-
eration in the determination of plasma VPA levels.
Author Contributions
Conceived and designed the experiments: SE ATC ASF PM. Performed the experiments: SE
SDS LN ANC ASF. Analyzed the data: SE ASF. Contributed reagents/materials/analysis tools:
ACR. Wrote the paper: SE PM.
References
1. Bauer PO, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic
strategies. J Neurochem. 2009; 110: 1737–1765. doi: 10.1111/j.1471-4159.2009.06302.x PMID:
19650870
2. Ross CA, Margolis RL, Becher MW,Wood JD, Engelender S, Cooper JK, et al. Pathogenesis of neuro-
degenerative diseases associated with expanded glutamine repeats: new answers, new questions.
Prog Brain Res. 1998; 117: 397–419. PMID: 9932422
3. Kawaguchi Y, Okamoto T, Taniwaki M, AizawaM, Inoue M, Katayama S, et al. CAG expansions in a
novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994; 8: 221–228. doi:
10.1038/ng1194-221 PMID: 7874163
4. Rüb U, Brunt ER, Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3
(Machado-Joseph disease). Curr Opin Neurol. 2008; 21: 111–116. doi: 10.1097/WCO.
0b013e3282f7673d PMID: 18317266
Chronic VPA Treatment in CMVMJD135 Mouse Model
PLOS ONE | DOI:10.1371/journal.pone.0141610 October 27, 2015 14 / 17
5. Barbeau A, Roy M, Cunha L, De Vincente AN, Rosenberg RN, NyhanWL, et al. The natural history of
Machado-Joseph disease. An analysis of 138 personally examined cases. Can J Neurol Sci. 1984; 11:
510–525. PMID: 6509398
6. Coutinho P, Andrade C. Autosomal dominant system degeneration in Portuguese families of the
Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord
motor functions. Neurology. 1978; 28: 703–709. PMID: 566869
7. Lima L, Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena
Portuguese family. Neurology. 1980; 30: 319–322. PMID: 7189034
8. Hoffner G, Djian P. Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Tox-
icity? Mol Neurobiol. 2014; doi: 10.1007/s12035-014-8932-1 PMID: 25336039
9. Seidel K, Den DunnenWFA, Schultz C, Paulson H, Frank S, De Vos RA, et al. Axonal inclusions in spi-
nocerebellar ataxia type 3. Acta Neuropathol. 2010; 120: 449–460. doi: 10.1007/s00401-010-0717-7
PMID: 20635090
10. Evert BO, Schelhaas J, Fleischer H, De Vos RAI, Brunt ER, Stenzel W, et al. Neuronal intranuclear
inclusions, dysregulation of cytokine expression and cell death in spinocerebellar ataxia type 3. Clin
Neuropathol. 2006; 25: 272–281. PMID: 17140157
11. Rüb U, De Vos RAI, Brunt ER, Sebestény T, Schöls L, Auburger G, et al. Spinocerebellar ataxia type 3
(SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive
neuronal intranuclear inclusions. Brain Pathol. 2006; 16: 218–227. doi: 10.1111/j.1750-3639.2006.
00022.x PMID: 16911479
12. Weber JJ, Sowa AS, Binder T, Hübener J. From Pathways to Targets: Understanding the Mechanisms
behind Polyglutamine Disease. BioMed Research International. 2014; 2014: 1–22. doi: 10.1155/2014/
701758
13. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the for-
est for the trees? Cell Mol Life Sci. 2007; 64: 2090–2103. doi: 10.1007/s00018-007-7079-x PMID:
17514356
14. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clini-
cal experience. CNS Drugs. 2002; 16: 695–714. PMID: 12269862
15. Shi Y, Gerritsma D, Bowes AJ, Capretta A, Werstuck GH. Induction of GRP78 by valproic acid is
dependent upon histone deacetylase inhibition. Bioorg Med Chem Lett. 2007; 17: 4491–4494. doi: 10.
1016/j.bmcl.2007.06.006 PMID: 17566732
16. Zádori D, Geisz A, Vámos E, Vécsei L, Klivényi P. Valproate ameliorates the survival and the motor per-
formance in a transgenic mouse model of Huntington’s disease. Pharmacol Biochem Behav. 2009; 94:
148–153. doi: 10.1016/j.pbb.2009.08.001 PMID: 19698736
17. Tsai L-K, Tsai M-S, Ting C-H, Li H. Multiple therapeutic effects of valproic acid in spinal muscular atro-
phy model mice. J Mol Med. 2008; 86: 1243–1254. doi: 10.1007/s00109-008-0388-1 PMID: 18649067
18. Feng H-L, Leng Y, Ma C-H, Zhang J, Ren M, Chuang D-M. Combined lithium and valproate treatment
delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral
sclerosis mouse model. Neuroscience. 2008; 155: 567–572. doi: 10.1016/j.neuroscience.2008.06.040
PMID: 18640245
19. Yi J, Zhang L, Tang B, HanW, Zhou Y, Chen Z, et al. Sodium valproate alleviates neurodegeneration in
SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4.
PLoS ONE. 2013; 8: e54792. doi: 10.1371/journal.pone.0054792 PMID: 23382971
20. Lin XP, Feng L, Xie CG, Chen DB, Pei Z, Liang XL, et al. Valproic acid attenuates the suppression of
acetyl histone H3 and CREB activity in an inducible cell model of Machado-Joseph disease. Int J Dev
Neurosci. 2014; 38: 17–22. doi: 10.1016/j.ijdevneu.2014.07.004 PMID: 25068645
21. Teixeira-Castro A, Ailion M, Jalles A, Brignull HR, Vilaça JL, Dias N, et al. Neuron-specific proteotoxicity
of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. HumMol Genet. 2011;
20: 2996–3009. doi: 10.1093/hmg/ddr203 PMID: 21546381
22. Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, Amorim M, Soares-Cunha C, Oliveira P, et al.
Chronic treatment with 17-DMAG improves balance and coordination in a newmouse model of
Machado-Joseph disease. Neurotherapeutics. 2014; 11: 433–449. doi: 10.1007/s13311-013-0255-9
PMID: 24477711
23. Sultan FA, Sweatt JD. The role of the Gadd45 family in the nervous system: a focus on neurodevelop-
ment, neuronal injury, and cognitive neuroepigenetics. Adv Exp Med Biol. 2013; 793: 81–119. doi: 10.
1007/978-1-4614-8289-5_6 PMID: 24104475
24. Akhtar RS, Ness JM, Roth KA. Bcl-2 family regulation of neuronal development and neurodegenera-
tion. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research. 2004; 1644: 189–203. doi: 10.
1016/j.bbamcr.2003.10.013
Chronic VPA Treatment in CMVMJD135 Mouse Model
PLOS ONE | DOI:10.1371/journal.pone.0141610 October 27, 2015 15 / 17
25. Yamauchi J, Miyamoto Y, Murabe M, Fujiwara Y, Sanbe A, Fujita Y, et al. Gadd45a, the gene induced
by the mood stabilizer valproic acid, regulates neurite outgrowth through JNK and the substrate paxillin
in N1E-115 neuroblastoma cells. Exp Cell Res. 2007; 313: 1886–1896. doi: 10.1016/j.yexcr.2007.02.
019 PMID: 17428471
26. Xie C, Edwards H, Xu X, Zhou H, Buck SA, Stout ML, et al. Mechanisms of synergistic antileukemic
interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer
Res. 2010; 16: 5499–5510. doi: 10.1158/1078-0432.CCR-10-1707 PMID: 20889917
27. Morris JA, Dorner AJ, Edwards CA, Hendershot LM, Kaufman RJ. Immunoglobulin binding protein
(BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the
secretion of selective proteins. J Biol Chem. 1997; 272: 4327–4334. PMID: 9020152
28. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibi-
tors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001; 413: 739–743.
doi: 10.1038/35099568 PMID: 11607033
29. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone deacetylase inhibition by
sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease
mice. J Neurosci. 2003; 23: 9418–9427. PMID: 14561870
30. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al. Suberoylanilide hydroxamic acid,
a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease.
Proc Natl Acad Sci USA. 2003; 100: 2041–2046. doi: 10.1073/pnas.0437870100 PMID: 12576549
31. Chou A-H, Chen S-Y, Yeh T-H, Weng Y-H, Wang H-L. HDAC inhibitor sodium butyrate reverses tran-
scriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
Neurobiol Dis. 2011; 41: 481–488. doi: 10.1016/j.nbd.2010.10.019 PMID: 21047555
32. Hahnen E, Hauke J, Tränkle C, Eyüpoglu IY, Wirth B, Blümcke I. Histone deacetylase inhibitors: possi-
ble implications for neurodegenerative disorders. Expert Opin Investig Drugs. 2008; 17: 169–184. doi:
10.1517/13543784.17.2.169 PMID: 18230051
33. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y, et al. Sodium butyrate amelio-
rates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum
Mol Genet. 2004; 13: 1183–1192. doi: 10.1093/hmg/ddh131 PMID: 15102712
34. Rouaux C, Panteleeva I, René F, Gonzalez de Aguilar J-L, Echaniz-Laguna A, Dupuis L, et al. Sodium
valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms
but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci. 2007; 27:
5535–5545. doi: 10.1523/JNEUROSCI.1139-07.2007 PMID: 17522299
35. Hoffmann K, Czapp M, Löscher W. Increase in antiepileptic efficacy during prolonged treatment with
valproic acid: role of inhibition of histone deacetylases? Epilepsy Res. 2008; 81: 107–113. doi: 10.
1016/j.eplepsyres.2008.04.019 PMID: 18538545
36. Yamauchi J, Miyamoto Y, Murabe M, Fujiwara Y, Sanbe A, Fujita Y, et al. Gadd45a, the gene induced
by the mood stabilizer valproic acid, regulates neurite outgrowth through JNK and the substrate paxillin
in N1E-115 neuroblastoma cells. Exp Cell Res. 2007; 313: 1886–1896. doi: 10.1016/j.yexcr.2007.02.
019 PMID: 17428471
37. Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, et al. A combination of a ribo-
nucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers
BIM-dependent apoptosis in head and neck cancer. Oncotarget. 2012; 3: 31–43. PMID: 22289787
38. Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, et al. Valproic acid enhances bosuti-
nib cytotoxicity in colon cancer cells. Int J Cancer. 2009; 124: 1990–1996. doi: 10.1002/ijc.24158
PMID: 19123474
39. Tremolizzo L, Carboni G, RuzickaWB, Mitchell CP, Sugaya I, Tueting P, et al. An epigenetic mouse
model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl
Acad Sci USA. 2002; 99: 17095–17100. doi: 10.1073/pnas.262658999 PMID: 12481028
40. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic
acid: a retrospective study. Can J Neurol Sci. 1997; 24: 240–244. PMID: 9276111
41. Martin CK, Han H, Anton SD, Greenway FL, Smith SR. Effect of valproic acid on body weight, food
intake, physical activity and hormones: results of a randomized controlled trial. J Psychopharmacol
(Oxford). 2009; 23: 814–825. doi: 10.1177/0269881108091595
42. Verrotti A, D’Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic
acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011; 12: e32–43. doi: 10.1111/j.
1467-789X.2010.00800.x PMID: 20880119
43. Rüb U, Brunt ER, Petrasch-Parwez E, Schöls L, Theegarten D, Auburger G, et al. Degeneration of
ingestion-related brainstem nuclei in spinocerebellar ataxia type 2, 3, 6 and 7. Neuropathol Appl Neuro-
biol. 2006; 32: 635–649. doi: 10.1111/j.1365-2990.2006.00772.x PMID: 17083478
Chronic VPA Treatment in CMVMJD135 Mouse Model
PLOS ONE | DOI:10.1371/journal.pone.0141610 October 27, 2015 16 / 17
44. Rüb U, De Vos RAI, Schultz C, Brunt ER, Paulson H, Braak H. Spinocerebellar ataxia type 3
(Machado-Joseph disease): severe destruction of the lateral reticular nucleus. Brain. 2002; 125: 2115–
2124. PMID: 12183356
45. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone
protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding
site in suppression of caspase-7 activation. J Biol Chem. 2003; 278: 20915–20924. doi: 10.1074/jbc.
M212328200 PMID: 12665508
46. Liu H, Bowes RC, Van deWater B, Sillence C, Nagelkerke JF, Stevens JL. Endoplasmic reticulum
chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in
renal epithelial cells. J Biol Chem. 1997; 272: 21751–21759. PMID: 9268304
47. Gorbatyuk MS, Gorbatyuk OS. The Molecular Chaperone GRP78/BiP as a Therapeutic Target for
Neurodegenerative Disorders: A Mini Review. J Genet Syndr Gene Ther. 2013; 4. doi: 10.4172/2157-
7412.1000128 PMID: 23750325
48. Pereira CMF. Crosstalk between Endoplasmic Reticulum Stress and Protein Misfolding in Neurodegen-
erative Diseases. ISRN Cell Biology. 2013; 2013: 1–22. doi: 10.1155/2013/256404
49. Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. Evaluation of the mood-stabilizing agent
valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. J
Parasitol. 2008; 94: 555–557. doi: 10.1645/GE-1331.1 PMID: 18564764
50. Löscher W. Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in ani-
mals. PharmWeekbl Sci. 1992; 14: 139–143. PMID: 1502015
51. Valor LM, Guiretti D, Lopez-Atalaya JP, Barco A. Genomic landscape of transcriptional and epigenetic
dysregulation in early onset polyglutamine disease. J Neurosci. 2013; 33: 10471–10482. doi: 10.1523/
JNEUROSCI.0670-13.2013 PMID: 23785159
52. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central ner-
vous system disorders. Nat Rev Drug Discov. 2008; 7: 854–868. doi: 10.1038/nrd2681 PMID:
18827828
53. Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neu-
rol. 2003; 28: 126–129. PMID: 12699863
54. Grosso S, Mostardini R, Piccini B, Balestri P. Body mass index and serum lipid changes during treat-
ment with valproic acid in children with epilepsy. Ann Pharmacother. 2009; 43: 45–50. doi: 10.1345/
aph.1L414 PMID: 19066323
55. Isojärvi J. Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms.
Seizure. 2008; 17: 111–119. doi: 10.1016/j.seizure.2007.11.007 PMID: 18164216
56. Verrotti A, Loiacono G, Laus M, Coppola G, Chiarelli F, Tiboni GM. Hormonal and reproductive distur-
bances in epileptic male patients: emerging issues. Reprod Toxicol. 2011; 31: 519–527. doi: 10.1016/j.
reprotox.2011.02.002 PMID: 21338669
57. Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet. 1995; 32: 724–727. PMID:
8544193
58. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf. 2006; 29:
1–21. PMID: 16454531
59. Ornoy A. Valproic acid in pregnancy: howmuch are we endangering the embryo and fetus? Reprod
Toxicol. 2009; 28: 1–10. doi: 10.1016/j.reprotox.2009.02.014 PMID: 19490988
60. FELASA working group on revision of guidelines for health monitoring of rodents and rabbits, Mähler
Convenor M, Berard M, Feinstein R, Gallagher A, Illgen-Wilcke B, et al. FELASA recommendations for
the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimen-
tal units. Lab Anim. 2014; 48: 178–192. doi: 10.1177/0023677213516312 PMID: 24496575
61. Silva-Fernandes A, Costa M do C, Duarte-Silva S, Oliveira P, Botelho CM, Martins L, et al. Motor unco-
ordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intra-
nuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis. 2010; 40: 163–176. doi: 10.1016/j.
nbd.2010.05.021 PMID: 20510362
62. Rafael JA, Nitta Y, Peters J, Davies KE. Testing of SHIRPA, a mouse phenotypic assessment protocol,
on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice. MammGenome. 2000; 11: 725–728.
PMID: 10967129
63. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, et al. Characterization of progressive
motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci. 1999; 19:
3248–3257. PMID: 10191337
64. Franklin KBJ. Paxinos and Franklin’s The mouse brain in stereotaxic coordinates. Fourth edition.
Amsterdam: Academic Press, an imprint of Elsevier; 2013.
65. Zar JH. Biostatistical analysis. 4th ed. Upper Saddle River, N.J: Prentice Hall; 1999.
Chronic VPA Treatment in CMVMJD135 Mouse Model
PLOS ONE | DOI:10.1371/journal.pone.0141610 October 27, 2015 17 / 17
